Abstract
Objectives In South Korea, 13,745 cases of coronavirus disease (COVID-19) have been reported as of 19 July, 2020. To examine the spatiotemporal changes in the transmission potential, we present regional estimates of the doubling time and reproduction number (Rt) of COVID-19 in the country.
Methods Daily series of confirmed COVID-19 cases in the most affected regions were extracted from publicly available sources. We employed established mathematical and statistical methods to investigate the time-varying reproduction numbers of the COVID-19 in Korea and its doubling time, respectively.
Results At the regional level, Seoul and Gyeonggi Province have experienced the first peak of COVID-19 in early March, followed by the second wave in early June, with Rt exceeding 3.0 and mean doubling time ranging from 3.6 to 10.1 days. As of 19 July, 2020, Gyeongbuk Province and Daegu are yet to experience a second wave of the disease, where the mean Rt reached 3.5-4.4 and doubling time ranging from 2.8 to 4.6 days during the first wave.
Conclusions Our findings support the effectiveness of control measures against COVID-19 in Korea. However, the easing of the restrictions imposed by the government in May 2020 facilitated a second wave in the greater Seoul area.
Highlights
South Korea has experienced two spatially heterogenous waves of COVID-19.
Seoul and Gyeonggi Province experienced two waves of COVID-19 in March and June.
In the densely populated Seoul and nearby areas, reproduction numbers exceeded 3.0.
The easing of the social distancing measures resulted in the second wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) [No. 2018R1C1B6001723] to ES. For GC and AT, this work was supported by RAPID NSF No. 2026797.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
